Back to top

BioNTech price target lowered to $119 from $126 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on BioNTech (BNTX) to $119 from $126 and keeps an Overweight rating on the shares. Biotech could ben...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BioNTech SE Sponsored ADR (BNTX)